NAS10026,944+1.18%S&P7,385+0.42%GOLD$4,067−1.12%BTC$75,586−0.47%VIX25.28−10.29%latest tape · as of 18:01 UTC
The Screen · Consumer Cyclical · Packaging & Containers
Silgan Holdings Inc.
SLGN · the NYSE · USD · Market cap $4.5B · 17,320 employees
Silgan Holdings Inc., together with its subsidiaries, manufactures and sells rigid packaging solutions for consumer goods products in the United States and internationally.
FAIL · Does not pass the screen
41.64 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 18:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price41.64 USD at the 5 Nov 2026 close
Our value readUndervalued vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.17, read 2026-11-02
Ethical does not pass the values gate
Price41.64 USD
Fair value61.00
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-21Read Markup39.90+4.4% to today ✓Distribution gives way to Markup with deal news in the headlines
2026-07-02Read Distribution40.91+1.8% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Silgan Holdings Inc. holds its Markup at $41.64. Consolidating, no directional conviction, held for 9 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 9 days
Price at the screen
$41.64
Valuation
17.20 trailing · 10.54 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.64
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
46.26%
Below 33%
Interest-bearing debt is 46.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
17.77%
Below 49%
Money owed to the company is 17.8% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Silgan's business is in a permissible area, but its interest-bearing debt is about 46% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SLGN's ethical verdict changes
Today SLGN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 30% discount to our $61.00 fair value, 1.60% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 31.7% discount to the base estimate.
Where our models see it going: fair-value estimate $61.00, with a range of $61.00 to $85.32, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Everyday cans mask a packaging value trap
Think of the metal tins and plastic caps that keep your soup or shampoo sealed. Silgan makes those in volume, yet the business sits in a cyclical corner of consumer goods where volumes swing with spending and commodity costs. A forward multiple of 11.5 times and a 29 percent gap to our fair value look tempting on paper, but the 6 percent revenue growth and 4 percent profit margin tell a flatter story.
We pass because the low multiple is the warning, not the bargain. Peak earnings in good years often compress the price-to-earnings ratio without lifting long-run returns, and the unknown moat leaves little protection when metal prices or retail demand turn. ROE at 13 percent is respectable yet nothing that offsets the cyclical exposure.
The ethical screen clears, and analysts see upside to 56 dollars, yet none of that overcomes the risk of buying at what may prove the top of the cycle. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SLGN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$42.66+8.5%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53.
2026-10-29Markup$39.30-1.5%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$39.90+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$39.90+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$39.90+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$39.90+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markup$39.90+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markup$39.90+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markup$39.90+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markup · changed$39.90+12.6%Entry 8
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (12 analysts) rates it strong buy, with a mean price target of $53.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
